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Abstract
Background
Treatment decision-making regarding immunosuppressive therapy is challenging for individ-
uals with lupus. We assessed the effectiveness of a decision aid for immunosuppressive
therapy in lupus nephritis.
Methods and findings
In a United States multicenter, open-label, randomized controlled trial (RCT), adult women
with lupus nephritis, mostly from racial/ethnic minority backgrounds with low socioeconomic
status (SES), seen in in- or outpatient settings, were randomized to an individualized, cultur-
ally tailored, computerized decision aid versus American College of Rheumatology (ACR)
lupus pamphlet (1:1 ratio), using computer-generated randomization. We hypothesized that
the co-primary outcomes of decisional conflict and informed choice regarding immunosup-
pressive medications would improve more in the decision aid group. Of 301 randomized
women, 298 were analyzed; 47% were African-American, 26% Hispanic, and 15% white.
Mean age (standard deviation [SD]) was 37 (12) years, 57% had annual income of <
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$40,000, and 36% had a high school education or less. Compared with the provision of the
ACR lupus pamphlet (n = 147), participants randomized to the decision aid (n = 151) had (1)
a clinically meaningful and statistically significant reduction in decisional conflict, 21.8 (stan-
dard error [SE], 2.5) versus 12.7 (SE, 2.0; p = 0.005) and (2) no difference in informed
choice in the main analysis, 41% versus 31% (p = 0.08), but clinically meaningful and statis-
tically significant difference in sensitivity analysis (net values for immunosuppressives posi-
tive [in favor] versus negative [against]), 50% versus 35% (p = 0.006). Unresolved
decisional conflict was lower in the decision aid versus pamphlet groups, 22% versus 44%
(p < 0.001). Significantly more patients in the decision aid versus pamphlet group rated infor-
mation to be excellent for understanding lupus nephritis (49% versus 33%), risk factors
(43% versus 27%), medication options (50% versus 33%; p� 0.003 for all); and the ease of
use of materials was higher in the decision aid versus pamphlet groups (51% versus 38%; p
= 0.006). Key study limitations were the exclusion of men, short follow-up, and the lack of
clinical outcomes, including medication adherence.
Conclusions
An individualized decision aid was more effective than usual care in reducing decisional con-
flict for choice of immunosuppressive medications in women with lupus nephritis.
Trial registration
Clinicaltrials.gov, NCT02319525.
Author summary
Why was this study done?
• Lupus kidney disease is a serious immune system condition that can lead to kidney fail-
ure and dialysis in young women, if not treated appropriately. Effective treatment with
immune-blocking medicines is available, but patients report difficulty making informed
decisions that weigh benefits and risks, such as side effects.
• No patient decision aids are available for lupus medication decision-making.
• The research team made an online decision aid for women with lupus kidney disease,
with extensive input from individuals with lupus. The aid can be individualized to help
patients make informed decisions about immune-blocking medicines for lupus.
What did the researchers do and find?
• In 301 women with lupus kidney disease across four centers, researchers assessed
whether an online decision aid improved lupus treatment decisions, compared with the
use of a paper pamphlet on lupus kidney disease from the American College of
Rheumatology.
• Compared with women who received the lupus pamphlet, women who used the deci-
sion aid reported feeling less doubt about their medication choice.
Decision aid for patients with lupus nephritis
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• More women who used the online decision aid said that the information source was
easy to use, compared with women who used the lupus pamphlet.
What do these findings mean?
• This study provides evidence that a decision aid for women with kidney disease may
help patients feel more confident in their treatment choices.
Introduction
Systemic lupus erythematosus (SLE) is a chronic disease primarily affecting young women,
with significant morbidity and mortality. Compared with whites, African-Americans and His-
panic groups have higher SLE incidence, worse disease severity and outcomes [1,2], and
greater mortality [3]. Approximately 35% of SLE patients present with lupus nephritis and
50%–60% develop it within 10 years [4,5]. Lupus nephritis accounts for 2% of end-stage renal
disease (ESRD) in the United States [6]. It is significantly more prevalent and has worse out-
comes in African-Americans and Hispanic groups [4,7].
Treatment of lupus nephritis with immunosuppressive medications is complex, especially
for young women, and carries risks of infertility, teratogenicity, and serious infections. Many
patients face difficult decisions, necessitating clear patient–provider communication and
shared decision-making. Decision aids can support shared decision-making to ensure that
treatment plans are consistent with patients’ values [8]. Moreover, patient participation in
decision-making can improve outcomes [9,10], including medication adherence [11–14].
Adherence to lupus medications, including immunosuppressive drugs, is lower in women of
racial/ethnic groups [15,16]. Low adherence is associated with poorer outcomes [17]. These
data suggest that a decision aid may increase patient participation in decision-making and ulti-
mately improve adherence in vulnerable patient populations, who are less engaged in their
care.
To our knowledge, no lupus decision aids are available. In the U.S., 41% of Hispanic groups,
24% of African-Americans, and 9% of whites have below basic health literacy skills [18]. Lower
health literacy and numeracy are associated with greater risk aversion [19] and may interfere
with the delivery of guideline-concordant care in racial/ethnic minorities with lupus. As an
example, many patients decline immunosuppressive medications due to fear of side effects
and lack of recognition of benefits, including prevention of ESRD [20]. Most lupus educational
materials are written at readability levels above the recommended sixth grade reading level
and have only adequate suitability (no assessment of numeracy level) [21]. Decision aids that
address patients’ literacy and numeracy levels are therefore warranted.
Based on qualitative work with patients [22–24] and the comparative effectiveness research
(CER) data on benefits and risks of immunosuppressive medications in lupus nephritis [25–
27], we developed an individualized, culturally tailored, computerized decision aid for medica-
tion decision-making for patients with lupus nephritis. The lupus decision aid was created in
the first year followed by its testing in years 2–3 of a 3-year Patient-Centered Outcomes
Research Institute (PCORI) contract; the details of decision aid development are available in a
previous publication [28].
Decision aid for patients with lupus nephritis
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tool; UAB, University of Alabama at Birmingham;
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We assessed whether patients randomized to an individualized, culturally and linguistically
appropriate, computerized decision aid were more likely to make more informed treatment
decisions compared with patients randomized to an American College of Rheumatology
(ACR) patient information lupus pamphlet. This randomized controlled trial (RCT), the Indi-
vidualized Decision aid for Diverse Women with Lupus Nephritis (IDEA-WON) study, tested
the efficacy of our individualized lupus decision aid. We hypothesized that the lupus decision
aid would lead to (1) a greater reduction in decisional conflict and a higher likelihood of mak-
ing an informed choice (co-primary outcomes); (2) less discordance in patients’ preferred role
in decision-making between the desired versus actual role in decision-making, and improved
patient–physician communication (secondary outcomes); and (3) being acceptable and feasi-
ble. The study was designed to capture populations most affected by lupus nephritis by involv-
ing centers that serve large numbers of vulnerable populations. Our study included
predominantly African-American and Hispanic subjects, because lupus nephritis is more
prevalent and more severe in women from minority backgrounds [4,7].
Methods
Study population, study sites, randomization, and Clinicaltrials.gov
registration
We conducted a multicenter, parallel, two-arm, open-label RCT, comparing the ACR lupus
paper pamphlet (S1 Text) to an individualized, culturally and linguistically appropriate deci-
sion aid for women with lupus nephritis called shared decision-making in lupus electronic
tool (SMILE). All outcomes were patient assessed and patient reported, and neither patients
nor assessors were blinded. Women with lupus nephritis were recruited from four geographi-
cally diverse sites (University of Alabama at Birmingham [UAB], University of California at
San Francisco [UCSF], Baylor College of Medicine, and Ohio State University). After obtain-
ing written informed consent, we randomized participants using a computer-generated ran-
domization process based upon a permuted variable block design, stratified by study site and
language (English versus Spanish), and designed by a biostatistician. Our study was registered
at Clinicaltrials.gov (NCT02319525) and was approved by each of the participating sites’
Human Subjects Studies Programs. Our trial protocol published elsewhere provides additional
details of the study protocol and the development of the decision aid with extensive multi-
stakeholder input, including patients, clinicians, patient advocacy organization leaders, and
researchers [28]. This study is reported as per the Consolidated Standards of Reporting Trials
(CONSORT) guideline (S1 CONSORT Checklist).
Subject eligibility, recruitment, and retention
Adult women (�18 years) of all race/ethnicities currently having a lupus nephritis flare and
considering change or initiation of an immunosuppressive medication (current flare) or who
had a prior lupus nephritis flare and were at risk for a future lupus nephritis flare (at risk for
nephritis flare) were eligible. Lupus nephritis flare was defined as an increase in disease activ-
ity, indicated by an increase in proteinuria and/or serum creatinine concentration, abnormal
urine sediment, or a reduction in creatinine clearance rate as a result of active disease, similar
to previous studies [29,30,31,32] and as defined by the ACR lupus nephritis guideline [33]. A
lupus nephritis flare is an indication for initiation or change of immunosuppressive medica-
tion. Study exclusions were male sex, dialysis, renal transplant, or planned renal transplant (S2
Text). Initial enrollment of only African-American and Hispanic women (given our focus on
Decision aid for patients with lupus nephritis
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racial/ethnic minorities) was expanded to also include white and Asian women to increase the
generalizability of the study findings and increase enrollment.
Participants were identified through screening outpatient clinic lists for diagnostic codes
for lupus nephritis in the clinical electronic health record (EHR) databases or by direct physi-
cian referral of people with a new diagnosis of lupus nephritis in in- or outpatient setting.
Research associates then conducted a medical record review to confirm eligibility using the
preceding inclusion/exclusion criteria; all patients met the 1997 ACR revised classification cri-
teria for lupus [34] and were diagnosed with lupus nephritis by a rheumatologist based on the
presence of proteinuria, urinary casts, a kidney biopsy, and/or other laboratory tests (creati-
nine, blood urea nitrogen, etc.). The research associates obtained written informed consent
and Health Insurance Portability and Accountability Act (HIPAA) authorization from each
participant prior to study participation and conducted study visits during the patient’s regu-
larly scheduled outpatient visits. Participants were enrolled from March 15, 2015, to November
4, 2016. All patients were recruited at routine outpatient clinic appointments, and all study
procedures were completed at routine clinic appointments.
Intervention: Individualized, culturally appropriate, computerized
decision aid versus pamphlet
Patients with lupus nephritis were randomized in a 1:1 ratio to the provision of the decision
aid or the ACR lupus paper pamphlet (S1 Text) in the doctor’s office after completing baseline
pre-intervention assessments (demographics, health literacy, numeracy, etc.). Follow-up
assessments were kept to a minimum due to the nature of the study and to minimize missing
data. At 3 months, study subjects assessed patient–physician communication either during a
routine clinic visit, via phone (if no clinic visit), or via mail (if not reachable via phone and in
clinic).
The decision aid was developed based on the International Patient Decision aid Standards
(IPDAS) [35] with multi-stakeholder group input (individuals with lupus, patient coinvestiga-
tors, clinicians, and researchers) and underwent iterative modification and pilot testing. It was
tailored to the target population’s numeracy and health and graphical literacy levels [36]. It
incorporated barriers to and facilitators of medication decision-making in women with lupus
nephritis [22–24] and the CER data on medication benefits and risks [25–27]. Themes gener-
ated from nominal groups of patients with lupus nephritis, including African-American, His-
panic, Asian, and white women [22–24], were incorporated into the decision aid content and
presentation. Because we recruited similar target patient populations for the nominal groups
and the trial (those from racial/ethnic minority groups with low socioeconomic status [SES] or
low literacy), themes and content generated were culturally tailored to included populations.
Additionally, patient research partners and patient advocacy leaders (study coinvestigators)
consisted of racial/ethnic minorities as well as white women, who reviewed the lupus decision
aid content for cultural appropriateness and provided feedback.
Individualization of the decision aid (S1 Fig) was done in several ways. We provided spe-
cific immunosuppressive medication comparisons based on the options being considered (or
possible to be considered in the future), given the treatment phase (induction versus mainte-
nance) and the current treatment(s) (S1 Fig) [28]. We gave optional links to additional infor-
mation embedded in the decision aid, including sections on pregnancy, breastfeeding, fertility,
and glucocorticoids side effects (S1 Fig). Optional links on how to manage specific adverse
events associated with immunosuppressive medications were provided. We also provided the
decision aid in both English and Spanish to allow patients to view it in the language they
Decision aid for patients with lupus nephritis
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choose. Images of the lupus decision aid are provided as supporting information (S1 Fig). The
decision aid was administered using tablet computers.
All patients randomized to the decision aid read information describing disease manifesta-
tions, with relative benefits and harms for different treatments options based on their personal
histories. The decision aid also included links to support groups. Participants were able to
stop, rewind, and review the content. The co-primary and secondary outcomes were measured
after administration of the decision aid/pamphlet, followed by the clinic visit with the health-
care provider, which was audiotaped (S3 Text). The informed consent, pamphlet, decision aid,
and all data collection materials were available in English and Spanish. The control group
received the ACR patient information lupus pamphlet (S1 Text) that provided information
about lupus and its treatment, including the use of immunosuppressive drugs.
Study outcomes
Co-primary outcomes were change in the decisional conflict score and the proportion with an
informed choice post-intervention; secondary outcomes were physician–patient communica-
tion measures and patient preference for decision-making (see S3 Text). Decisional conflict
was measured using the low literacy version of the Decisional Conflict Scale (DCS), a well-vali-
dated self-administered instrument [37]. The low literacy version has 10 items with 3 response
categories: yes, unsure, and no. Four subscale scores consisting of uncertainty about choice,
feeling informed, values clarity, and feeling supported in decision-making were also calculated.
DCS (and subscale) scores range from 0 (best) to 100 (worst) and scores�25 are consistent
with clinically significant residual decisional conflict [38].
Informed value-concordant choice was assessed using a validated multidimensional model
of informed choice [39,40] that individually assessed and then combined three constructs
regarding immunosuppressive medications: values (favoring or against) [41], objective knowl-
edge [42], and choice (decision to or not to start immunosuppressive medication) [43]. Value
(10 value statements; for detailed methods, see S4 Text) and knowledge (20 true/false ques-
tions; S4 Text) items were developed based on the results of a previously conducted nominal
group study [23,24]. Participants were classified into those favoring versus against the use of
immunosuppressive medications using the median value score (negative values were reverse
coded). Choice predisposition towards starting immunosuppressive medications was assessed
using a 15-point scale (anchor scores were 1 [willing] and 15 [not willing] and uncertain in the
center) in response to, “If your doctor recommended that you take an immunosuppressive
drug for your lupus nephritis, would you be willing to take one?” Participants’ choices were
classified as “willing” (1–7), “undecided” (8), or “unwilling” (9–15). Informed choice refers to
one based on adequate knowledge (score of�75%) and concordant with one’s values related
to immunosuppressive medications (favoring or against).
In contrast to the main analysis, in which we categorized values above or below the median
as favoring/not favoring immunosuppressive medications (statistical approach), we performed
a sensitivity analysis for informed choice by reclassifying participants according to the net
score as positive or negative on value statements (clinical approach), comparing value state-
ments favorable towards immunosuppressive medications (e.g., “Taking medicine now is
important to increase my chance of being healthy in the future”—positive values) with value
statements that were not favorable (e.g., “It is not a good idea to take medicines for years”—
negative values). This was an a priori protocol-specified analysis [28].
Preferred role in decision making was assessed using the Control Preferences Scale [44].
We used this instrument to ask participants their preferred role as well as the actual role they
played. The latter was asked only in those with a current lupus nephritis flare. We classified
Decision aid for patients with lupus nephritis
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responses into active (active/active shared), collaborative, or passive roles (passive/passive
shared) [44].
Patient–physician communication and care processes were assessed using the Interpersonal
Processes of Care short form (IPC-SF), an 18-item validated patient-reported patient–physi-
cian communication and care processes measure [45]. Scores range from 18 to 90, with higher
scores indicating better communication/care.
Analysis of the audiotaped baseline physician–patient visit was performed using the Active
Patient Participation Coding Scheme (APPC), a validated instrument to assess indicators and
facilitators of patient participation [46]. Clinic visits were only audiotaped and coded among
participants with a current flare and who agreed to be recorded. We assessed active patient
participation and patient-centered communication by the doctor[47]. Each utterance was
coded by trained coders and scored, with higher scores indicating better patient participation/
communication.
Acceptability of the decision aid/pamphlet (information quality and quantity, presentation
style, and usefulness) was assessed using a validated acceptability survey [48] on a 4-point scale
ranging from “excellent” to “poor.” Feasibility of the decision aid/pamphlet and the study pro-
cedures was assessed with a self-administered questionnaire [49]. Participants rated the ease of
using the decision aid/pamphlet, survey comprehension, content and readability, and the time
needed to review the decision aid/pamphlet and questionnaires on 5-point agreement scales.
Study covariates
In addition to race/ethnicity, education, income, and language, the following were assessed:
(1) health literacy, using the validated 18-item Short Assessment of Health Literacy tool
(SAHL-E and SAHL-S) [50], for which the number of words read and associated correctly are
summed (possible range = 0–18; low health literacy = 0–14); (2) subjective numeracy, using an
8-question self-administered scale [51] (possible range = 1–6; low subjective numeracy = 0–3);
(3) graphical literacy, using the short form version by Galesic and colleagues [52] (possible
range = 0–4; low graphical literacy = 0–3); and (4) trust in physicians using the validated
11-item self-administered scale [53,54], in which responses are coded on a 5-point Likert scale
(totally disagree to totally agree; possible range = 11–55; low trust = 11–43).
Statistical analyses
Statistical analyses were performed using SAS software (SAS version 9.4, Cary, NC). We used
two-sample t tests to compare study arms for continuous outcomes (change in DCS scores;
secondary outcomes, IPC-SF score, and audiotaped physician–patient interaction scores), and
chi-squared test for categorical outcomes (informed choice; secondary outcome, role concor-
dance on control preferences scale; acceptability; and feasibility). To control for possible base-
line imbalances in decisional conflict and informed choice, we also used analysis of covariance
(ANCOVA) and logistic regression to compare post-intervention decisional conflict and
informed choice, respectively, accounting for baseline values (pre-intervention decisional con-
flict and pre-intervention knowledge, values, and choice, respectively).
We examined treatment heterogeneity by performing subgroup analyses by language, race/
ethnicity, SES, type of scenario (current flare versus at risk for flare), numeric literacy, income,
health literacy, graphical literacy, and trust in physicians score, using linear (decisional con-
flict) and logistic (informed consent) regression models, adjusting for baseline covariates. As
some of these analyses were not prespecified (graphical literacy, trust in physicians score), a
Bonferroni correction was used to account for multiple testing for all analyses, as a conserva-
tive approach.
Decision aid for patients with lupus nephritis
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The primary analysis was on an intent-to-treat basis. All p-values were two sided, and
p< 0.05 was considered statistically significant, except subgroup analyses in which we used
the Bonferroni correction to account for multiple testing (p< 0.0008 considered significant [=
0.05/63]). We considered a 10% difference between study arms in the proportion of patients
achieving a favorable or unfavorable outcome to be clinically meaningful. We assessed whether
change in knowledge versus clarification of choices mediated the change in decisional conflict
related to decision aid, assessed using the mediation analyses [55].
Our proposed sample size of 200 patients, with 90 patients in each study arm (10% loss to
follow-up; 45 each Hispanic and African-American), had an 80% power to detect a large effect
size difference of 0.60 between group means on the DCS score using a two-sided type I error
rate of 0.05 and a 21% difference in informed choice using a one-sided type I error rate of 0.05,
based on published results, 12% in the usual care versus 33% in the decision aid group [56]. An
effect size of 0.4–0.8 represents a clinically meaningful difference in the DCS, discriminating
between those who make and delay decisions [57]. Because of a low recruitment rate of His-
panic women, we enrolled 301 participants, aiming to have as close to 90 Hispanic patients for
analyses as possible. The study protocol was modified to recruit white and Asian participants
to improve generalizability.
Patient and public involvement
Two patients and four patient advocacy organization leaders (LMH, SCR, GSE, LM) were
study coinvestigators who participated as key stakeholders in study design and conduct,
reviewed results, and coauthored the study. Qualitative work with patients to define the con-
tent and focus of the decision aid [22–24], and extensive piloting of decision aid [28], helped
us maintain a strong patient-centered focus.
Ethical approval and consent to participate
The UAB’s Institutional Review Board approved this study, and all investigations were con-
ducted in conformity with ethical principles of research. The study was also approved by the
Institutional Review Boards at each of the other study sites, including the Baylor College of
Medicine, Houston, TX, the Ohio State University, Columbus, OH, and UCSF, San Francisco,
CA.
Results
Baseline patient characteristics
Of the 301 participants enrolled in 2015–2016, three withdrew consent before receiving either
study intervention; 298 participants randomized to the decision aid (n = 151) or pamphlet
(n = 147) generated data (Fig 1, CONSORT diagram). The mean age (standard deviation
[SD]) was 37 (SD, 12) years, 57% had annual incomes of less than $40,000, 36% had high
school educations or less, 34% were married, and 85% were nonwhite. The average health liter-
acy score was 16.8 (SD, 2.5). Characteristics by study arm are described in Table 1. There were
no significant baseline differences between the groups, except the difference in immunosup-
pressive choice (Table 1).
Primary outcomes
Compared with the group receiving the ACR lupus pamphlet, participants who received the
decision aid had less decisional conflict, as demonstrated by clinically meaningfully and statis-
tically significantly larger reductions in the DCS post-intervention—a 21.8 (SE, 2.5)- versus a
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12.7 (SE, 2.0)-point decrease (p = 0.005 from two-sample t test). Post-intervention decisional
conflict scores and distribution are shown in Fig 2. After accounting for the amount of pre-
intervention decisional conflict, the participants who received the decision aid had signifi-
cantly less post-intervention decisional conflict compared with the pamphlet group, 11.5 (SE,
1.4) versus 24.8 (SE, 2.3) (p< 0.001 from ANCOVA). The proportion of patients with
Fig 1. CONSORT diagram for patient selection. The figure includes 1,005 patients prescreened using electronic medical records and/or in-person screening.
Of these, 704 were excluded, 19 declined to participate (12 had no time; 5 were not interested in participating in a research study, and 2 did not want any more
information about medications for lupus), and 1 was excluded due to psychosis; An asterisk (�) indicates that the remaining 684 did not meet eligibility, and the
reasons were as follows: no nephritis (n = 388); candidate for or already had renal transplant (n = 162); dialysis (n = 99); potential but no clinic appointments
(n = 29); and miscellaneous (n = 6): needed biopsy (n = 1); kidney disease not due to lupus (n = 1); lupus complications, nonrenal (n = 1); none of the scenario
matches any treatment option for the patient (n = 1); and not sufficient evidence from clinic notes (n = 2). ACR, American College of Rheumatology.
https://doi.org/10.1371/journal.pmed.1002800.g001
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Table 1. Baseline demographic and clinical characteristics of study participants.
Characteristics All
(n = 298) Mean ± SEM or
N (%)
Decision Aid
(n = 151) Mean ± SEM or
N (%)
Pamphlet
(n = 147) Mean ± SEM or
N (%)
p-
value
Age in years 37.3 ± 0.7 37.1 ± 1.0 37.6 ± 1.0 0.72
Race/Ethnicity, n (%) 0.73
Non-Hispanic Black 141 (47.3%) 70 (46.4%) 71 (48.3%)
Hispanic/Latino 78 (26.2%) 41 (27.1%) 37 (25.2%)
Non-Hispanic White 44 (14.8%) 20 (13.2%) 24 (16.3%)
Asian 20 (6.7%) 11 (7.3%) 9 (6.1%)
Other 13 (4.4%) 7 (4.6%) 6 (4.1%)
Not answered 2 (0.7%) 2 (1.3%) —
Marital status 0.39
Don’t know/Not answered 3 (1.0%) 3 (2.0%) —
Widowed 5 (1.7%) 3 (2.0%) 2 (1.4%)
Never married 145 (48.7%) 76 (50.3%) 69 (46.9%)
Divorced or separated 43 (14.4%) 19 (12.6%) 24 (16.3%)
Married or living with a partner 102 (34.2%) 50 (33.1%) 52 (35.4%)
Education 0.10
Don’t know/Not answered 3 (1.0%) 3 (2.0%) —
High school or less 106 (35.6%) 48 (31.8%) 58 (39.5%)
Greater than high school 189 (63.4%) 100 (66.2%) 89 (60.5%)
Employment 0.25
Retired 8 (2.7%) 5 (3.3%) 3 (2.0%)
Working 111 (37.2%) 54 (35.8%) 57 (38.8%)
Keeping house 35 (11.7%) 17 (11.3%) 18 (12.2%)
Unable to work 91 (30.5%) 45 (29.8%) 46 (31.3%)
Going to school 15 (5.0%) 4 (2.6%) 11 (7.5%)
Looking for work 12 (4.0%) 8 (5.3%) 4 (2.7%)
Had a job, but not working 9 (3.0%) 5 (3.3%) 4 (2.7%)
Other 16 (5.4%) 12 (8.0%) 4 (2.7%)
Don’t know/Not answered 1 (0.3%) 1 (0.7%) —
Annual household Income 0.57
Less than $40,000 169 (56.7%) 89 (58.9%) 80 (54.4%)
$40,000–$80,000 44 (14.8%) 18 (11.9%) 26 (17.7%)
$80,000 or more 32 (10.7%) 17 (11.3%) 15 (10.2%)
Don’t know/Not answered 53 (17.8%) 27 (17.9%) 26 (17.7%)
Size of household 3.21 ± 0.1 3.4 ± 0.2 3.02 ± 0.1 0.12
Language (survey, decision aid) 0.69
English 255 (85.6%) 128 (84.8%) 127 (86.4%)
Spanish 43 (14.4%) 23 (15.2%) 20 (13.6%)
Flare type 0.88
Current 68 (22.8%) 35 (23.2%) 33 (22.4%)
Future 230 (77.2%) 116 (76.8%) 114 (77.5%)
Health literacy—SAHL 16.9 ± 0.1 16.8 ± 0.2 16.88 ± 0.2 0.87
Subjective Numeracy Scale 3.8 ± 0.1 4.0 ± 0.1 3.75 ± 0.1 0.11
Ability Subscale 3.8 ± 0.1 3.9 ± 0.1 3.64 ± 0.1 0.11
Preference Subscale 3.9 ± 0.1 4.0 ± 0.1 3.86 ± 0.1 0.24
Short Graph Literacy Scale 1.6 ± 0.1 1.6 ± 0.1 1.63 ± 0.1 0.99
Trust in Physician Scale 46.5 ± 0.4 46.2 ± 0.5 46.81 ± 0.5 0.42
(Continued)
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unresolved clinically significant decisional conflict (score�25) post-intervention was lower in
the decision aid versus the pamphlet group, 22% versus 44% (p< 0.001 from ANCOVA). In
the mediation analyses, we found that the reduction in decisional conflict was not mediated by
the clarification of choices post-intervention (p = 0.298 for mediation by clarification of
choices) or by improved knowledge (p = 0.063 for mediation by knowledge).
There was no difference in the informed choice regarding immunosuppressive medications
in the main analysis, 41% in the decision aid versus 31% in pamphlet group (p = 0.08 from chi-
squared test). There was also not a significant difference in informed choice after accounting
for baseline knowledge, values, and choice (p = 0.10 from logistic regression). Using an alter-
nate definition for patient values regarding immunosuppressive medications (a priori protocol
specified [28]; sensitivity analysis), more women in the decision aid group made an informed
choice compared with those in the pamphlet group, 50% versus 35% (p = 0.006). Using the test
for superiority as per protocol [28], results were statistically significant for both main and sen-
sitivity analyses (one-sided p = 0.04 and p = 0.003; Table 2; see statistical analysis section).
Compared with the provision of the ACR lupus pamphlet, decision aid use was associated
with a statistically significant reduction in all DCS subscale scores (p< 0.05) except one: the
feeling supported in decision-making subscale (p = 0.056; Table 2). Of the three informed
choice components, compared with the participants in the ACR lupus pamphlet group, partic-
ipants in the decision aid group had statistically significantly higher objective knowledge
scores post-intervention (76.9 [SE, 1.0] versus 73 [SE, 1.1]; p = 0.045), and a clinically mean-
ingful (�10% absolute difference) but not statistically significantly higher proportion changed
Table 1. (Continued)
Characteristics All
(n = 298) Mean ± SEM or
N (%)
Decision Aid
(n = 151) Mean ± SEM or
N (%)
Pamphlet
(n = 147) Mean ± SEM or
N (%)
p-
value
Pre-intervention DCS score 35.4 ± 1.7 33.4 ± 2.4 37.48 ± 2.5 0.23
Uncertainty subscale 35.0 ± 2.2 33.5 ± 3.2 36.56 ± 3.2 0.49
Informed subscale 44.9 ± 2.2 42 ± 3.1 47.96 ± 3.2 0.18
Values clarity subscale 39.7 ± 2.3 37.8 ± 3.3 41.67 ± 3.4 0.41
Support subscale 23.2 ± 1.7 21.7 ± 2.5 24.83 ± 2.3 0.36
Pre-intervention unresolved clinically significant decisional conflict
on DCS (score�25)
178 (59.7%) 85 (56.3%) 93 (63.3%) 0.31
Pre-intervention informed choice for immunosuppressives 0.12
Informed 84 (28.2%) 49 (32.4%) 35 (23.8%)
Not informed 213 (71.5%) 101 (66.9%) 112 (76.2%)
Pre-intervention informed choice components
Knowledge (percentage correct) 74.6 ± 0.7 74.3 ± 0.9 74.8 ± 1.0 0.72
Values for immunosuppressives 0.98
Against 134 (45.0%) 68 (45.0%) 66 (44.9%)
In favor 164 (55.0%) 83 (55.0%) 81 (55.1%)
Choice for immunosuppressives 0.01
Undecided 115 (38.6%) 47 (31.3%) 68 (46.3%)
Unwilling 34 (11.4%) 23 (15.3%) 11 (7.5%)
Willing 148 (49.7%) 80 (53.3%) 68 (46.3%)
Missing: SAHL was missing for 3 decision aid, 1 pamphlet; Short Graph Literacy was missing for 2 decision aid, 1 pamphlet; Pre-intervention informed choice missing
for 1 decision aid; Choice for immunosuppressives at baseline was missing for 1 decision aid.
Abbreviations: DCS, Decisional Conflict Scale; SAHL, Short Assessment of Health Literacy.
https://doi.org/10.1371/journal.pmed.1002800.t001
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from unwilling or undecided pre-intervention to willing to take immunosuppressive medica-
tions post-intervention (47% versus 32%; p = 0.078).
In preplanned subgroup analyses, there was clinically meaningful and statistically signifi-
cant reduction in the DCS score in the decision aid versus pamphlet group in patients with
lower income and lower graphical literacy (Fig 3). A lower proportion had an unresolved clini-
cally significant decisional conflict post-intervention in the decision aid versus pamphlet
group in participants using the English (7% decision aid versus 43% pamphlet) versus the
Spanish (52% versus 55%) language version (Fig 4; S5 Text). Respectively, a lower proportion
of subjects in decision aid and pamphlet groups reported unresolved clinically significant deci-
sional conflict post-intervention, with higher (21% versus 42%) versus lower (39% versus 58%)
health literacy, with higher (16% versus 43%) versus lower education level (33% versus 47%),
Fig 2. Pre and Post-intervention decisional conflict (0–100; higher score indicates more conflict). Dashed line represents the
threshold for unresolved clinically significant decisional conflict (�25) on the DCS. The box plot shows the median, indicated by the
solid line, and 25th and 75th percentiles as the lower and upper bounds of the box. The whiskers represent the minimum and
maximum values. DCS, Decisional Conflict Scale.
https://doi.org/10.1371/journal.pmed.1002800.g002
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and more (16% versus 38%) versus less (36% versus 61%) trust in physicians (Fig 4; S5 Text).
The remainder of subgroup analyses for informed choice were not significant based on Bon-
ferroni-adjusted p-value (S5 Text and S6 Text).
Secondary outcomes, acceptability, feasibility and adverse events
There were no statistically significant differences in any of the secondary outcomes in the deci-
sion aid versus pamphlet groups (higher score = better outcome for all), respectively: (1)
IPC-SF mean (SD) scores were 83.6 (7.7) versus 83.1 (7.3) (p = 0.50; n = 296); (2) 94% versus
85% of patients had concordance in desired versus actual role played in decision-making using
the control preferences scale (p = 0.25; n = 68; only in those with current flare); and (3) mean
(SD) patient active participation score, 8.1 (7.2) versus 9.2 (7.3) (p = 0.80) in an analysis of
audiotaped conversations (n = 33). Patient-centered communication by the doctor in audio-
taped conversation showed a trend towards statistical significance, 5.1 (2.1) versus 3.7 (1.9)
(p = 0.06). We found that 27% of the participants preferred cyclophosphamide as the treatment
option, 33% other immunosuppressive medications (19% mycophenolate mofetil; 1% calci-
neurin inhibitors; 13% azathioprine), 29% were unsure of which treatment of the two treat-
ment options they preferred, and 9% chose none (see S4 Text for treatment scenarios and
choices; 2% missing).
More patients rated the decision aid versus pamphlet information as “excellent” for under-
standing lupus nephritis impact (49% versus 33%), risk factors (43% versus 27%), medication
Table 2. Co-primary outcomes: DCS score and informed choice.
Outcomes Decision Aid Pamphlet Difference between Treatment Arms
Mean (SEM) or N
(%)
Mean (SEM) or N
(%)
Odds Ratio (95%
CI)
Mean Difference (95%
CI)
p-value�
Change in DCS total score 21.8 (2.5) 12.7 (2.0) N/A 9.1 (2.8–15.5) 0.005
Change in DCS subscale scores
Change in Uncertainty subscale 17.3 (3.5) 5.0 (3.2) N/A 12.2 (2.9–21.6) 0.01
Change in Informed subscale 30.6 (3.3) 21.7 (2.8) N/A 8.9 (0.4–17.4) 0.04
Change in Values Clarity subscale 27.2 (3.4) 16.8 (3.1) N/A 10.3 (1.3–19.4) 0.03
Change in Support subscale 12.4 (2.5) 6.1 (2.2) N/A 6.4 (−0.2 to 12.9) 0.06
Unresolved clinically significant decisional conflict on DCS
(score�25)
34 (22.5%) 65 (44.2%) 0.4 (0.2–0.6) N/A <0.001
Informed choice for Immunosuppressives 1.5 (1.0–2.5) N/A 0.08
Informed 62 (41.1%) 46 (31.3%)
Not informed 89 (58.9%) 101 (68.7%)
Informed choice components
Knowledge (percentage correct) 76.9 (1.0) 73.9 (1.1) N/A 3.0 (0.1–5.9) 0.04
Values for immunosuppressives 0.8 (0.5–1.3) N/A 0.34
Against 72 (47.7%) 62 (42.2%)
In favor 79 (52.3%) 85 (57.8%)
Choice for immunosuppressives 1.6 (0.9–2.7)� N/A 0.10
Undecided 30 (19.9%) 41 (27.9%)
Unwilling 11 (7.3%) 18 (12.2%)
Willing 110 (72.9%) 88 (59.9%)
�p-value was obtained from two-sample t tests (for continuous outcomes) or chi-squared tests (for categorical outcomes).
Abbreviations: CI, confidence interval; DCS, Decisional Conflict Scale; N/A, not applicable; SEM, standard error of the mean.
https://doi.org/10.1371/journal.pmed.1002800.t002
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options (50% versus 33%), evidence about medications (47% versus 24%), and information
about other patients (42% versus 22%) (p< 0.05 for all; Table 3). More patients in the decision
aid versus pamphlet group agreed or strongly agreed that the decision aid was easy to use—
51% versus 38% for the pamphlet (p = 0.006; Table 3). The majority (65%–90%) in both
groups agreed strongly that study procedures including viewing of the decision aid or pam-
phlet (process, study questionnaires, extra time needed for the study) were feasible, with 65%–
90% in both groups agreeing or strongly agreeing (Table 3).
One patient in each of the two intervention groups died: one at 53 days post-intervention,
caused by right ventricular failure after cardiovascular surgery (decision aid), and one at 22
Fig 3. Subgroup analyses for decisional conflict scale (DCS) score. Differences that are statistically significant after correcting for multiple comparisons are
represented with a filled square; others are presented with an open square. The hashed vertical line represents a difference of zero in DCS scores post-intervention,
i.e., no difference between the decision aid and pamphlet groups. An asterisk (�) indicates statistically significant Bonferroni-corrected p-value (p< 0.0008). The
categorization for subgroups were as follows: graphical literacy: low, 0–2, High, 3–4; SAHL: low, 0–14, high,>14; numeracy: low, 0–3, high, 4–6; trust in physicians:
low,<44, high, 44–55. DCS, Decisional Conflict Scale; SAHL, Short Assessment of Health Literacy.
https://doi.org/10.1371/journal.pmed.1002800.g003
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days post-intervention, caused by subarachnoid hemorrhage (pamphlet); both were unrelated
to the study procedures or interventions. No other adverse events were reported.
Discussion
In this multicenter RCT in 301 women with lupus kidney disease that included people of a
racial/ethnic minority background and those with low SES, low literacy, or low income, an
individualized, culturally tailored, computerized lupus nephritis decision aid for immunosup-
pressive medications (SMILE) was associated with a clinically meaningful and statistically sig-
nificant reduction in decisional conflict compared with an ACR lupus information pamphlet
Fig 4. Subgroup analyses for unresolved decisional conflict scale (DCS) score of� 25. Differences that are statistically significant after correcting for multiple
comparisons are represented with a filled square; others are presented with an open square. The hashed vertical line represents an odds ratio of one for unresolved
DCS scores post-intervention, i.e., no difference in the proportion of people with unresolved decisional conflict between the decision aid and the pamphlet groups.
An asterisk (�) indicates statistically significant Bonferroni-corrected p-value (p< 0.0008). The categorizations for subgroups were as follows: graphical literacy: low,
0–2, high, 3–4; SAHL: low, 0–14; high,>14; numeracy: low, 0–3; high, 4–6; trust in physicians: low,<44, high, 44–55. DCS, Decisional Conflict Scale; SAHL, Short
Assessment of Health Literacy.
https://doi.org/10.1371/journal.pmed.1002800.g004
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Table 3. Acceptability and feasibility of lupus nephritis decision aid versus lupus pamphlet and feasibility of the study procedures.
Acceptability and Feasibility Assessments Decision Aid Pamphlet p-value��
(n = 151) (n = 147)
Patient acceptability of information and presentation: Percentage of subjects marking "Excellent”
Impact of lupus nephritis 74 (49.0%) 49 (33.0%) 0.006
Risk factors 64 (42.4%) 40 (27.2%) 0.006
Medication options 76 (50.3%) 49 (33.3%) 0.003
Evidence about medications 71 (47.0%) 35 (23.8%) <0.001
Studies about others 64 (42.4%) 32 (21.8%) <0.001
Feasibility of the study intervention
The education guide�was easy to use. 0.006
(Missing) — 1 (0.7%)
Strongly Disagree 1 (0.7%) 3 (2.0%)
Disagree 1 (0.7%) 13 (8.8%)
Neither Agree nor Disagree 73 (48.3%) 74 (50.3%)
Agree 75 (49.7%) 55 (37.4%)
Strongly Agree 1 (0.7%) 1 (0.7%)
Feasibility of the study procedures
The questions were easy to see/hear. 0.70
(Missing) — 1 (0.7%)
Strongly Disagree 1 (0.7%) 2 (1.4%)
Disagree 5 (3.3%) 3 (2.0%)
Neither Agree nor Disagree 5 (3.3%) 7 (4.8%)
Agree 70 (46.4%) 75 (51.0%)
Strongly Agree 70 (46.4%) 59 (40.1%)
The questions were easy to answer. 0.10
(Missing) — 1 (0.7%)
Strongly Disagree 1 (0.7%) 3 (2.0%)
Disagree 3 (2.0%) 9 (6.1%)
Neither Agree nor Disagree 18 (11.9%) 27 (18.4%)
Agree 73 (48.3%) 63 (42.9%)
Strongly Agree 56 (37.1%) 44 (29.9%)
The process did not take too long. 0.23
(Missing) — 1 (0.7%)
Strongly Disagree 4 (2.6%) 3 (2.0%)
Disagree 25 (16.6%) 13 (8.8%)
Neither Agree nor Disagree 22 (14.6%) 29 (19.7%)
Agree 56 (37.1%) 63 (42.9%)
Strongly Agree 44 (29.1%) 38 (25.8%)
I did not mind spending extra time at my doctor visit to understand the risks and benefits of treatment. 0.23
(Missing) — 1 (0.7%)
Strongly Disagree 1 (0.7%) 4 (2.7%)
Disagree 6 (4.0%) 1 (0.7%)
Neither Agree nor Disagree 12 (7.9%) 13 (8.8%)
Agree 63 (41.7%) 57 (38.8%)
Strongly Agree 69 (45.7%) 71 (48.3%)
�Education guide refers to the ACR pamphlet or the computerized, individualized decision aid.
��p-value using chi-squared test.
Each question is in italics.
Abbreviation: ACR, American College of Rheumatology.
https://doi.org/10.1371/journal.pmed.1002800.t003
Decision aid for patients with lupus nephritis
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002800 May 8, 2019 16 / 23
(updated version at ACR website at https://www.rheumatology.org/I-Am-A/Patient-
Caregiver/Diseases-Conditions/Lupus). A lower proportion in the decision aid group had
unresolved clinically significant conflict. There was no statistical difference in the informed
choice regarding immunosuppressive drugs between the decision aid and the pamphlet groups
in the main analysis using the median patient value, but there was a clinically meaningful and
statistically significant difference in the informed choice between groups in the prespecified
sensitivity analysis that used net patient value (a clinical approach). In general, people are
either favorable or not favorable towards immunosuppressive medications, which influences
their decision-making and the final choice to use or not to use them for treatment. Therefore,
the analysis considering the net patient value regarding the use of immunosuppressive medica-
tions (favoring versus against; a clinical approach) may be more clinically more meaningful
than the analyses using a median value (a statistical approach). The number needed to treat to
benefit (NNTB) with decision aid was 5 for a resolved decisional conflict (opposite of unre-
solved) and 7–10 for informed choice for immunosuppressive medication (sensitivity versus
main analysis). The decision aid was tested in a population of women with lupus nephritis, in
which the majority of the patients had low SES and many had low health literacy and numer-
acy or were non-English speaking. The lack of significance in certain subgroups (Hispanic
women) is likely related to lack of power for this subgroup analysis, but might also indicate a
lower efficacy; this needs to be explored in future studies. Even if a Bonferroni correction were
applied because we had co-primary outcomes, the change in DCS would still be statistically
significant at α = 0.025 (= 0.05/2) and the difference in informed choice in main analysis
would remain nonsignificant.
A large-scale implementation trial of this self-administered computerized decision aid
(SMILE) in 16 busy U.S. clinical practices has been recently funded by PCORI and is under-
way. SMILE will be available free of cost in the public domain and can be administered using
any touchscreen computer.
In a Cochrane systematic review of 105 studies, the use of the decision aid was associated
with people being more knowledgeable, better informed, and clearer about their values and
they played a more active role in their treatment with moderate- to high-quality evidence [10].
The magnitude of the effect on decisional conflict was similar in participants with low versus
high education level, health literacy, or graphical literacy. Racial/ethnic minorities and individ-
uals with lupus with limited socioeconomic resources have barriers to optimal treatment [22–
24]. Decision aids have succeeded in improving outcomes in other conditions, when devel-
oped for the target population [58], similar to ours. We believe that the use of the lupus nephri-
tis decision aid can play a role in improving outcomes of the group of patients with lupus
nephritis.
This study focused on women from racial/ethnic minorities, with a majority with low SES
and low graphical literacy, and many with low health literacy and numeracy skills, or who
were non-English speaking. To our knowledge, this is the first study to provide data support-
ing the efficacy of an individualized, culturally tailored, computerized decision aid in lupus
nephritis. In a previous study, a lupus decision board was developed to improve the quality of
time spent in medical consultations [59], but no data on further development of a decision aid
were published.
In a related field of behavioral interventions involving medication adherence in lupus [60],
pharmacist-led counseling was associated with improved adherence compared with physician
counseling [61], while mobile text messaging with reminders did not improve medication
adherence [62]. To our knowledge, no lupus decision aids are available, and none of the educa-
tional or behavioral interventions in lupus have previously been tested in a high-risk patient
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population with low SES, low health literacy and numeracy, and/or non-English–speaking
patients, in contrast to our study.
We incorporated formative work [22–24], state-of-the-art CER [25–27], and multi-stake-
holder input to develop an individualized, computerized, patient decision aid tailored to
women with lupus nephritis facing a critical medication decision. Few decision aids have been
developed to support decision-making for an analogous high-risk patient population, i.e., Afri-
can-Americans, low SES, and low graphical and health literacy. We believe that this tool, avail-
able in English and Spanish, can facilitate and improve shared decision-making for lupus
nephritis treatments in clinical practice and that it should lead to higher patient satisfaction
and engagement. Whether it will improve disease outcomes over time will require further
study. The tool will be available free of charge in the public domain and can be self-adminis-
tered using touchscreen computers.
Our study has some limitations. Study findings are not generalizable to men, because men
were not involved in the tool’s development or testing. This decision aid is specific to lupus
nephritis, as it is the most common and most well studied of all organ-threatening lupus mani-
festations, for which multiple treatments are available. It can be adapted to develop a tool spe-
cific for other lupus manifestations with minor modifications, because the treatments for other
lupus manifestations are similar to that of lupus nephritis. The effect of decision aid on long-
term lupus outcomes was not tested but needs to be tested in future studies. Translations into
other languages are needed, and the inclusion of a larger number of Asian and Native Ameri-
can women in future testing is needed. This will further improve the generalizability of this
tool to all women with lupus nephritis. The decision aid was self-administered to patients in
the clinic waiting room; whether it can be adapted for at-home use by patients before a clinic
visit is unknown, and needs to be tested. Assessment of exploratory outcomes, including renal
function, proteinuria, etc., was not possible due to heterogeneity of performance of these mea-
sures in routine clinical care across four sites, limited study resources, and the inclusion of
fewer patients with current lupus nephritis flare than anticipated. Our patient decision aid,
SMILE, was administered on a tablet computer compared with the control intervention, a
paper pamphlet, which represents two different methods of intervention. The method of inter-
vention may have contributed to the success of our intervention.
Study strengths include that we sought input from a wide range of patients of all race/eth-
nicities, including Spanish-speaking patients, and adhered to IPDAS principles for decision
aid development [35]. Our study was a multicenter study with geographical diversity; included
vulnerable populations who are at risk for poor outcomes, including those from racial/ethnic
minority groups, with low educational level, income, health, and graphical literacy; and desig-
nated the standard of care (ACR lupus paper pamphlet) as the attention control. High ratings
on the acceptability and feasibility of content and presentation indicated that our tool is user-
friendly.
In a diverse group of women with lupus nephritis, including those with low educational
level, income, health literacy, or graphical literacy, an individualized, culturally tailored, com-
puterized self-administered patient decision aid (SMILE) administered in clinic waiting rooms
was more effective than the usual practice (standard ACR paper pamphlet) for immunosup-
pressive medications decision-making. Large, multicenter trials are needed to establish the
generalizability of this benefit. In collaboration with our partners, the Lupus Foundation of
America (LFA) and the Arthritis Foundation (AF), further research is planned to understand
the best way to implement this tool in busy clinical practices and to widely disseminate this
decision aid to patients (e.g., smartphone application).
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